Berenberg Starts Arcus Biosciences (RCUS) at Buy

November 24, 2020 6:32 AM EST
Get Alerts RCUS Hot Sheet
Price: $29.40 -2.07%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 8 | New: 30
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Berenberg analyst Zhiqiang Shu initiates coverage on Arcus Biosciences (NYSE: RCUS) with a Buy rating and a price target of $50.00.

The analyst commented, "Arcus Bioscience is advancing an immuno-oncology pipeline that targets multiple levers for cancer treatment, allowing the company to utilise combination therapies to maximise clinical outcomes. The 10-year Gilead collaboration is a vote of confidence for Arcus’s robust research engine and provides long-term support. We initiate coverage with a Buy based on our view that Arcus’s potential to develop therapies for multiple cancers is under-appreciated."

For an analyst ratings summary and ratings history on Arcus Biosciences click here. For more ratings news on Arcus Biosciences click here.

Shares of Arcus Biosciences closed at $25.76 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage